Relationship between the GH-IGFs axis and the proliferation of bile duct cancer cell line QBC939 in vitro

Hepatobiliary and Pancreatic Diseases International

Volumn 7, Issue 1, 2008, Pages 76-81

  Cai, Hui Hua ^a   Sun, Yue Ming ^a   Bai, Jian Feng ^a   Shi, Yi ^a   Zhao, Han Lin ^a   Miao, Yi ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Bile duct cancer; Cell cycle; Growth hormone

Indexed keywords

GROWTH HORMONE; MESSENGER RNA; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN; SOMATOMEDIN B; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR;

ARTICLE; BILE DUCT CANCER; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN QBC939; CELL SUSPENSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IN SITU HYBRIDIZATION; IN VITRO STUDY;

BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CELL DIVISION; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; CYTOPLASM; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MITOGENS; RNA, MESSENGER; S PHASE;

EID: 39049107427     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Wang GH, Zhao TJ. Effects of total parenteral nutrition enriched with human growth hormone on protein metabolism and immune function in gastrointestional cancer patients. Chin J Gen Surg 2001;10:567.
2. Chen JY, Liang DM, Gan P, Lin J, Zhang Y, Luo KY. Study of recombinant human growth hormone on growth of human gastric cancer cell in vitro. Chin J Exp Surg 2004;21:521-523.
3. Farris GM, Miller GK, Wollenberg GK, Molon-Noblot S, Chan C, Prahalada S. Recombinant rat and mouse growth hormones: risk assessment of carcinogenic potential in 2-year bioassays in rats and mice. Toxicol Sci 2007;97:548-561.
4. Shen Q, Lantvit DD, Lin Q, Li Y, Christov K, Wang Z, et al. Advanced rat mammary cancers are growth hormone dependent. Endocrinology 2007;148:4536-4544.
5. Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Kaprara A, Blakeman J, Vainas I, et al. Growth hormone-binding protein is directly and IGFBP-3 is inversely associated with risk of female breast cancer. Eur J Endocrinol 2007;156:187-194.
6. Rudd MF, Webb EL, Matakidou A, Sellick GS, Williams RD, Bridle H, et al. Variants in the GH-IGF axis confer susceptibility to lung cancer. Genome Res 2006;16:693-701.
7. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet 2002; 360:273-277.
8. Jenkins PJ, Mukherjee A, Shalet SM. Does growth hormone cause cancer? Clin Endocrinol (Oxf) 2006;64:115-121.
9. Rodriguez S, Gaunt TR, Day IN. Molecular genetics of human growth hormone, insulin-like growth factors and their pathways in common disease. Hum Genet 2007;122: 1-21.
10. Ibrahim YH, Yee D. Insulin-like growth factor-I and cancer risk. Growth Horm IGF Res 2004;14:261-269.
11. Shevah O, Laron Z. Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Horm IGF Res 2007;17:54-57.
12. Matyja V, Kos-Kudla B, Foltyn W, Strzelczyk J, Latos W, Marek B, et al. Detection of colorectal lesions by using autofluorescence colonoscopy in acromegalics and their relation to serum growth hormone and insulin-like growth factor-1 levels. Neuro Endocrinol Lett 2006;27:639-643.
13. Kong FM, Anscher MS, Washington MK, Killian JK, Jirtle RL. M6P/IGF2R is mutated in squamous cell carcinoma of the lung. Oncogene 2000;19:1572-1578.
14. Shi Y, Miao Q, Chen G, Zhao YP. Expression of growth hormone receptor in pancreatic carcinoma and effect of recombinant growth Hormone on pancreatic carcinoma proliferation and cell cycle. Chin J Exp Surg 2004;21: 441-443.
15. Ezaduar F, Van-Tol HT, Colenbrander B. Stimulatory effect of growth hormone on in vitro mataration of bovine oocytes is exerted through cumulus cells and not mediated by IGF-I. Mol Reprod Dev 1997;47:175-180.
16. Yin D, Vreeland F, Schaaf LJ, Millham R, Duncan BA, Sharma A. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: implications for cancer therapy. Clin Cancer Res 2007;13:1000-1009.
17. Zarandi M, Varga JL, Schally AV, Horvath JE, Toller GL, Kovacs M, et al. Lipopeptide antagonists of growth hormone-releasing hormone with improved antitumor activities. Proc Natl Acad Sci U S A 2006;103:4610-4615.
18. He XY, Xu GL, Xu RN, Ze ZM. Effect of reorganized human growth hormone on cell cycle kinetics in liver cancer in vitro. Hepatobiliary Pancreat Dis Int 2002;1:224-227.
19. Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE. Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 2006;13:583-592.
20. Ferrante E, Giavoli C, Porretti S, Vassallo E, Ronchi CL, Lania AG, et al. Evaluation of the components of the insulin-like growth factors system in GH-deficient adults: effects of twelve-month rhGH treatment. Horm Metab Res 2006;38:352-355.
21. Castro AM, Guerra-Júnior G. GH/IGF-1 and cancer: what's new in this association. [Article in Portuguese]. Arq Bras Endocrinol Metabol 2005;49:833-842.